Updates are available Correction dated 2021-11-27
Click to view Correction: https://doi.org/10.1007/s10875-021-01184-3
-
Authors
Fong, Siew-Wai
Yeo, Nicholas Kim-Wah
Chan, Yi-Hao
Goh, Yun Shan
Amrun, Siti Naqiah
Ang, Nicholas
Rajapakse, Menaka Priyadharsani
Lum, Josephine
Foo, Shihui
Lee, Cheryl Yi-Pin
Carissimo, Guillaume
Chee, Rhonda Sin-Ling
Torres-Ruesta, Anthony
Tay, Matthew Zirui
Chang, Zi Wei
Poh, Chek Meng
Young, Barnaby Edward
Tambyah, Paul A.
Kalimuddin, Shirin
Leo, Yee-Sin
Lye, David C.
Lee, Bernett
Biswas, Subhra
Howland, Shanshan Wu
Renia, Laurent
Ng, Lisa F. P.
- License Information
-
More Information
Article History
Received: 21 June 2021
Accepted: 17 September 2021
First Online: 30 October 2021
Change Date: 27 November 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10875-021-01184-3
Declarations
:
: The study design and protocols for the COVID-19 PROTECT study group were evaluated by National Healthcare Group (NHG) Domain Specific Review Board (DSRB) and approved under study number 2012/00917. Collection of healthy donor samples was approved by SingHealth Centralised Institutional Review Board (CIRB) under study number 2017/2806 and NUS IRB 04–140. Written informed consent was obtained from participants in accordance with the Declaration of Helsinki for Human Research.
: The authors affirm that human research participants provided informed consent for publication of the data.
: A patent application for the SFB assay has been filed (Singapore patent 10202009679P: A Method Of Detecting Antibodies And Related Products. YSG, LFPN, and LR). A patent application on the identified linear epitopes S14P5 and S20P2 has also been filed (PCT/SG2021/050178: Antibody-binding linear B cell epitopes of SARS-CoV and SARS-CoV-2. NKWY, SNA, GC, CMP, CYPL, RSLC, LR and LFPN). All other authors declare no competing interests.
